D. RFQ_f.pdf

REQUEST FOR QUOTATION

REQUEST NUMBER: 75N95022Q00553

DATE ISSUED: 09/01/2022

ISSUED BY CONTRACTING OFFICE: Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse (NIDA), Office of Acquisition (OA)

FOR INFORMATION CONTACT: Chandani Hangilipola, 301-480-7089, chandani.hangilipola@nih.gov

NORTH AMERICAN CLASSIFICATION SYSTEM (NAICS) CODE: 325414– Biological Product (except Diagnostic) Manufacturing

SMALL BUSINESS SIZE STANDARD: 1,250 employees

SET-ASIDE STATUS: No set-aside restrictions

Competition Status: This requirement is non-competitive

Non-Competitive (Single-sole Source (Including brand-name)) Determination:

This notice of proposed acquisition is posted as an intent to award a purchase order on a non-competitive basis to Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008

The Non-Competitive (Single-sole Source (Including brand-name)) Determination is based upon the market research conducted. Specifically, only one source is capable of providing the supplies or services required pursuant to FAR 13.106-1(b)(1)(i), only one source is reasonably available.

DATE QUOTATION DUE:

All responses to this request for quote must be received by 9:00 AM Eastern Standard Time, on September 13, 2022 and must reference the request number cited above. Responses must be submitted electronically to the contact person cited above. Fax responses will not be accepted.

IMPORTANT: This is a request for quotations. If you are unable to quote, please so indicate in a reply email to the contract specialist cited herein. This request does not commit the Government to pay any costs incurred in the preparation of the submission of this quotation or to contract for supplies or service. Supplies are of domestic origin unless otherwise indicated by quoter. Any representations and/or certifications attached to this Request for Quotation must be completed by the quoter.

Description of Requirement:

The National Center for Advancing Translational Sciences (NCATS) requires contractor results of profiling malaria compounds against a panel of human kinases for 4500 data points at one concentration and 300 IC50 curves. It is important to measure NCATS compounds’ activity against human lipid kinases so that a strategy can be developed to keep the malaria parasites killing activity and remove/reduce the human lipid kinase inhibitory activities.

Background Information:

The National Center for Advancing Translational Sciences (NCATS) is a translational science center that prides itself on its tremendously productive pipeline and is innovative in a number of ways. NCATS brings together a diverse range of scientists, including medicinal chemists, biologists, toxicologists, and engineers, to ultimately translate basic science into real products and services that help improve people’s lives.

Malaria affects an estimated 250 million people worldwide, particularly in the tropical regions of Sub-Saharan Africa and approximately 650,000 patients die each year. Even while on current therapies, patients remain infectious for a period of time, allowing further mosquito-borne transmission to others. Control of parasite transmission is critical for elimination and eradication of malaria. However, most antimalarial drugs are not active against sexual stage P. falciparum parasites — called gametocytes — which are responsible for the spread of malaria from person to person via mosquitoes.

NCATS has identified a series of (quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-ones with malaria parasites killing activity. Since similar compounds were reported as human kinases inhibitors, it is important to measure our compound’s activity against human kinases so that a strategy can be developed to keep the gametocyte killing activity and remove/reduce the human lipid kinase inhibitory activities. The goal of this work is to determine compounds’ single point inhibition as well as IC50 values against human kinases.

General Requirements:

Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform the Statement of Work below:

Specific Requirements:

The Contractor shall provide 4,500 data points (duplicate wells) kinases in single point inhibition determinations and 300 Kinases IC50 determinations.

QUOTER TERMS AND CONDITIONS: (To be completed by the Offeror):

1. Period of Performance OR Delivery Date After Receipt of Order:

2. Shipping Point (F.O.B. OR Destination):

3. Payment Discount Terms:

4. Open Market; GSA FSS Contract Number; Other Government Agency (OGA) Contract

Number, Government-wide Agency (GWAC) Contract Number; or National Institute of Health (NIH) Blanket Purchase Agreement (BPA) Number:

5. UEI:

6. Name of Company:

7. Street Address, City, State, Zip code:

8. Name of Person Authorized to Provide Quote:

9. Telephone Number and Email Address of Person Authorized to Provide Quote:

CONTRACT TYPE:

A Fixed-Price type Purchase Order award not exceeding the Simplified Acquisition Threshold is anticipated for any contract resulting from this requirement. The anticipated award date is 9/15/2022.

ADDITIONAL TERMS AND CONDITIONS, PROVISIONS, AND REPRESENTATIONS

FAR 52.252-1 Solicitation Provisions Incorporated by Reference (FEB 1998) This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at this/these address(es): www.acquisition.gov (End of provision)

FAR 52.252-2 Clauses Incorporated by Reference (FEB 1998) This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this/these address(es): www.acquisition.gov

(End of clause)

The FAR provisions and clauses are incorporated by reference and are provided in full text at https://www.acquisition.gov/

1. The provisions of FAR Clause 52.212-1 Instructions to Offerors—Commercial Items

(NOV 2021) is applicable to this solicitation.

2. The provisions of FAR Clause 52.212.2 Evaluation—Commercial Items (NOV 2021) is applicable to this solicitation. The Government will evaluate quotations or offers in accordance with FAR 13.106-2 and award a purchase order from this solicitation to the http://www.acquisition.gov/ https://www.acquisition.gov/ responsible offeror whose quote conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate quotes:

a. Technical capability of the service offered to meet the Government requirement;

b. Price; and

c. Past performance [see FAR 13.106-2(b)(3)].

3. The provisions of FAR Clause 52.212-3, Offeror Representations and Certifications— Commercial Items (NOV 2021), is applicable to this solicitation.

4. The provisions of FAR Clause 52.212-4, Contract Terms and Conditions—Commercial Items (NOV 2021) with Addenda: Stop Work Order, FAR Clause 52.242-15 (AUG 1989) is applicable to this solicitation.

5. The provisions of FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders—Commercial Items (JAN 2022) is applicable to this solicitation. See attachment.

In addition, the following FAR provisions and clauses are applicable to this solicitation and incorporated by reference:

52.204-7 System for Award Management (OCT 2018), 52.204-13 System for Award Management Maintenance (OCT 2018), 52.204-16 Commercial and Government Entity Code Reporting (AUG 2020), 52.204-18 Commercial and Government Entity Code Maintenance (AUG 2020).

The clause at HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015)

The following provisions and clauses apply to this acquisition and are incorporated as an attachment. Offerors MUST complete the provision at 52.204-24 and 52.204-26 pursuant to FAR 4.2103 Procedures and submit a completed copy as a separate document with their quotation.

1. FAR 52.204-24, Representation Regarding Certain Telecommunications and Video

Surveillance Services or Equipment (NOV 2021)

2. FAR 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video

Surveillance Services or Equipment (Aug 2020)

3. FAR 52.204-26, Covered Telecommunications Equipment or Services-Representation (Oct

2020)

4. NIH Invoice and Payment Provisions (Rev. 2/10/2021)

Delivery Date: The anticipated delivery date will be No later than November 15, 2022. Data will be sent to NCATS 30 days after receiving the compounds. Inspection and acceptance will be performed at NCATS located at 9800 Medical Center Drive, Rockville, MD 20852. A firm fixed price type order is anticipated to be awarded as a result of this RFQ.

SUMMARY STATEMENT:

Responses to this notice must include sufficient information to establish the interested parties’ bona-fide capabilities of providing the product or service. The response shall include: the unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability;

and environmental and energy efficiency considerations.